Business Context and Reporting Period
Autolus Therapeutics Plc filed a Form 8-K on January 21, 2026, reporting the entry into a Material Definitive Agreement. The registrant is a biopharmaceutical company incorporated in England and Wales, focused on the development of CAR-T products.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a contractual commitment regarding manufacturing supply.
Material Changes and Agreement Terms
On January 21, 2026, Autolus Limited, a wholly owned subsidiary, entered into a Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vector, a critical raw material for the Company's CAR-T products. Key terms include:
- Duration: Fixed term of ten years.
- Commitments: The Company committed to purchasing a minimum of 14 batches of lentiviral vector during the first two calendar years.
- Financial Commitment: The Company committed to purchasing a minimum value of EUR 25 million of products and services during the subsequent five-year period.
- Exclusivity: The agreement is non-exclusive, though AGC holds the first right to negotiate for new manufacturing activities related to the obe-cel product.
- Termination: Either party may terminate for default; the Company may terminate upon written notice subject to fee payments.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or general outlook commentary. The primary risk disclosed relates to the binding financial commitments and the reliance on AGC for critical raw materials. The full text of the agreement will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2026.
Investor Verification Checklist
- Verify the total potential financial exposure of the EUR 25 million commitment over the five-year period.
- Confirm the specific terms regarding termination fees payable by the Company.
- Review the upcoming Form 10-Q (Q1 2026) for the full text of the Master Service Agreement.
- Assess the impact of the 14-batch minimum purchase requirement on near-term cash flow.